|[December 20, 2013]
BioTime Reports Isolation of Novel Brain-Associated Cells From Human Embryonic Stem Cells
ALAMEDA, Calif. --(Business Wire)--
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and
markets products in the field of regenerative medicine reported today
the publication of a peer-reviewed scientific paper on the successful
generation of human cells with markers of particular cell types in the
human brain, potentially useful in the treatment of neurological
diseases such as Alzheimer's disease. The paper
published online (ahead of print) in the journal Regenerative
Medicine, characterizes the cells generated from human embryonic
stem cells using BioTime's proprietary PureStem™ technology. The
study reports that the new cell lines show the potential to become
cartilage and bone as well as brain-associated cells such as membranes
surrounding the brain called meninges and choroid plexus (the structure
in the brain that creates cerebrospinal fluid). These novel expandable
and highly purified progenitors have properties that may have a wide
array of future applications in the practice of orthopedics and
In the study titled "Human embryonic stem cell-derived neural crest
cells capable of expressing markers of osteochondral or
meningeal-choroid plexus differentiation," BioTime scientists published
for the first time the unique properties of two cell lines designated
E69 and T42 made using the company's PureStem™ technology. PureStem™
allows the scalable expansion of large numbers of desired cell types
starting with human embryonic stem cells. The PureStem™ cell
lines have the advantage that they have partially committed to become
one of the many tissues of the body. An additional competitive feature
of PureStem™ relates to the relative ease of producing large
quantities of these cells in a highly purified and identified state,
potentially leading to improved quality control. The company has
produced >200 diverse progenitors of the human body using this
technology. The cells described in today's scientific publication are
progenitors to tissues of the developing head called "neural crest"
cells. BioTime scientists demonstrated in the publication that the cells
could be induced to become diverse brain-associated cells by altering
the exposure of the cells to specific growth factors. The company has
filed for certain patent protection relating to the cells and the
methods described in the publication.
BioTime from time to time publishes scientific discoveries, such as
those reported today in Regenerative Medicine, to accelerate the
pace of research and discovery for devastating diseases such as
Alzheimer's disease, and to increase awareness of the cell lines in the
medical research markets. BioTime's subsidiary ES Cell International
offers the cell line for sale for research use only.
"To our knowledge, this is the first report of the isolation of these
important cell types," said Michael D. West, Ph.D., BioTime's Chief
Executive Officer. "The purity and scalability of the cells makes it an
easy matter for us to distribute them to the research markets. To date,
we have published data in the scientific literature relating to 10 of
the >200 cell types we have isolated from pluripotent stem cells. We
plan to continue to publish on additional cell types in the future."
Authors of today's publication included Hal Sternberg, Jianjie Jiang,
Pamela Sim, and Michael D. West of BioTime; Francois Binette of
OrthoCyte Corporation; Ariel Rinon, Ron Edgar, and Alina Shitrit of
LifeMap Sciences; David Larocca of ReCyte Therapeutics; Jennifer Kidd
and Karen B. Chapman of OncoCyte Corporation; and Jeffrey Janus of ES
Cell International. Additional information on PureStem™
technology presented by BioTime's CEO, Dr. Michael West, is available on
BioTime's web site in its video
About BioTime, Inc.
BioTime is a biotechnology company engaged in research and product
development in the field of regenerative medicine. Regenerative medicine
refers to therapies based on stem cell technology that are designed to
rebuild cell and tissue function lost due to degenerative disease or
injury. BioTime's focus is on pluripotent stem cell technology based on
human embryonic stem ("hES") cells and induced pluripotent stem ("iPS")
cells. hES and iPS cells provide a means of manufacturing every cell
type in the human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime's
therapeutic and research products include a wide array of proprietary PureStem™
progenitors, HyStem® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (a HyStem®
product) as a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. In addition,
BioTime has developed Hextend®, a blood plasma volume
expander for use in surgery, emergency trauma treatment and other
applications. Hextend® is manufactured and distributed
in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang
Corporation under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research,
therapeutic, and diagnostic use through its subsidiaries:
Asterias Biotherapeutics, Inc. is a new subsidiary which has acquired
the stem cell assets of Geron Corporation, including patents and other
intellectual property, biological materials, reagents and equipment
for the development of new therapeutic products for regenerative
OncoCyte Corporation is developing products and technologies to
diagnose and treat cancer.
Cell Cure Neurosciences Ltd. ("Cell Cure Neurosciences") is an
Israel-based biotechnology company focused on developing stem
cell-based therapies for retinal and neurological disorders, including
the development of retinal pigment epithelial cells for the treatment
of macular degeneration, and treatments for multiple sclerosis.
LifeMap Sciences, Inc. ("LifeMap Sciences") markets, sells and
distributes GeneCards®, the leading human gene
database, as part of an integrated database suite that also includes
the LifeMap Discovery™ database of embryonic development, stem
cell research and regenerative medicine, and MalaCards, the
human disease database.
ES Cell International Pte Ltd., a Singapore private limited company,
developed clinical and research grade hES cell lines and plans to
market those cell lines and other BioTime research products in
over-seas markets as part of BioTime's ESI (News - Alert) BIO Division.
BioTime Asia, Limited, a Hong Kong company, may offer and sell
products for research use for BioTime's ESI BIO Division.
OrthoCyte Corporation is developing therapies to treat orthopedic
disorders, diseases and injuries.
ReCyte Therapeutics, Inc. is developing therapies to treat a variety
of cardiovascular and related ischemic disorders, as well as products
for research using cell reprogramming technology.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
[ Back To Technology News's Homepage ]